Listing of all claims as amended

5 1.(PRESENTLY AMENDED) A peptide selected from the group having the formulae: R₁-A⁰-A¹-A²-Asp-Ala-A⁵-A⁶-Thr-A⁸-A⁹-A¹⁰-A¹¹-A¹²-Val-Leu-A¹⁵-A¹⁶-Leu-Ser-A¹⁹-A²⁰-A²¹-A²²-Leu-Gin-Asp-lle-A27-A28-A29-A30-R2

wherein R₁ is a member of the group consisting of a) PhAc, Hca, Dat, IndAc, Ipa, 1-Nac, 2-Nac, 1-Npr, 2-Npr, Ibu; CH₃(CH₃),CO, or HOOC(CH₃),CO, where n is an integer from 2 to 20,

10 and b) any other straight chain, branch chain, saturated, unsaturated or poly unsaturated aliphatic carboxyl group of 2-30 carbon atoms and any carbocyclic or heterocyclic aromatic carboxyl group of 3-8 carbon atoms containing at least one atom of the group S. N. and O in the heterocyclic ring. A⁰ is Phe, D-Phe, Arg, D-Arg, or a carbon nitrogen single-bond is absent

A1 is Tvr or His. 15 A2 is D-Arg or D-Cit.

A5 is lie or Val.

A6 is Phe, Tyr, Nal, or Phe(Y), in which Y=F, Cl, Br, or I,

A8 is Asn. D-Asn. Cit. D-Cit, Gln, D-Gln, Ser, D-Ser, Thr, D-Thr, Ala, D-Ala, Abu, D-Abu, or Aib, A9 is His, D-His, Amp, D-Amp, Gup, or D-Gup,

20 A¹⁰ is Tvr. Tvr(Et), Tvr(Me); Phe(Y), in which Y=H, F, Cl. Br. or I; Amp. His, Cha. Cho. Boa. Dip. Trp, Trp(For), Tpi, 1-Nal, 2-Nal, 3-Pal, 4-Pal, Phe(NH₂), or Phe(NO₂),

A¹¹ is His, D-His, Arg, D-Arg, Cit, Har, D-Har, Amp, D-Amp, Gup, or D-Gup,

A12 is Lys, D-Lys, Orn, D-Orn, Har, D-Har, Cit, D-Cit, NIe, or Ala,

A15 is Glv. Ala. Abu. Aib. Nle. Gln. Cit. or His.

25 A¹⁶ is Gln or Arg.

A19 is Ala or Abu. A20 is His, D-His, Arg, D-Arg, or Cit,

A21 is Lvs. D-Lvs. Orn. D-Orn. Cit. or D-Cit.

A²² is Leu, Ala or Aib.

30 A27 is Met. Leu, Nle, Abu, or D-Arg.

A28 is Arg. D-Arg, Har, D-Har, Ser, Asn, Asp, Ala, Abu, or Cit,

A²⁹ is Arg. D-Arg. Har. D-Har. Cit. D-Cit. or Agm.

A³⁰ is Arg. D-Arg, Har, D-Har, Cit, D-Cit, Agm, or is a earbon nitrogen or earbon exygen single bond absent.

35 R₂ is -NH₂, -NH-NH₂, -NH-OH, -NHR₃, -NR₃R₄, -OH, or -OR₃, in which R₃ and R₄ are any of C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkinyl, C₇₋₁₆ phenylalkyl, -C₆H₅, or -CH(C₆H₅)₂; provided that if A29 is Agm then A30 and R2 are absent, and if A30 is Agm then R2 is absent, and pharmaceutically acceptable salts thereof.

 (ORIGINAL) The compound of claim 1 wherein one or both of A¹¹ and A²⁰ are other than Arg, D-Arg, or Cit.

5 3. (ORIGINAL) A compound of claim 1 selected from the group consisting of:

[PhAc-Tyr¹, D-Arg², Phe(pCl)6, Amp9, Tyr(Me)¹0, Abu¹5, Nie²7, D-Arg²8, Har²²]hGH-RH(1-29)NH2 Peptide 67

10 [PhAc-Tyr 1 , D-Arg 2 , Phe(pCl) 6 , Amp 9 , Abu 15 , NIe 27 , D-Arg 28 , Har 28]hGH-RH(1-29)NH $_2$ Peptide 68

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, His⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 69

15
[CH₃(CH₂)₅CO-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁸]hGH-RH(1-29)NH₃.

Pentide 70

[HOOC(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, Abu¹⁵, Nie²⁷, D-Arg²⁸, Har²⁹]hGH-20 RH(1-29)NH₂ Peptide 71

 $[HOOC(CH_2)_{12}CO-Tyr^1, \ D-Arg^2, \ Phe(pCl)^6, \ Amp^9, \ Tyr(Me)^{10}, \ Abu^{15}, \ Nle^{27}, \ D-Arg^{26}, \ Har^{29}]hGH-RH(1-29)NH_2 \\ Peptide 72$

25 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Amp³, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²², D-Arg²³, Har²³]hGH-RH(1-29)NH₂ Peptide 73

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Amp⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁶, Har²⁵]hGH-RH(1-29)NH₂ Peptide 74

30

 $\label{eq:continuous} \mbox{[1-Nac-Tyr1, D-Arg2, Phe(pCl)6, Cit8, Amp9, Tyr(Me)10, His11, Abu15, Nle27, D-Arg26, Har29]nGH-RH(1-29)NH$_2$ Peptide 75$

 $[CH_3(CH_2)_eCO - Tyr^1, D-Arg^2, Phe(pCI)^6, Cit^6, Amp^9, Tyr(Me)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, 35 Har^{29}]nGH-RH(1-29)NH_2$ Peptide 76

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Amp⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nie²⁷, D-Arg²⁸, Har²⁸|hGH-RH(1-29)NH₂ Peptide 77

- [CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Amp³, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²², D-Arg²a, Har²a¹lhGH-RH(1-29)NH₂ Peptide 78
- $[CH_{3}(CH_{2})_{6}CO \ -Tyr^{1}, \ D-Arg^{2}, \ Phe(pCI)^{6}, \ Cit^{8}, \ His^{9}, \ Tyr(Et)^{10}, \ His^{11}, \ Abu^{15}, \ Nle^{27}, \ D-Arg^{28}, \\ 5 \ Har^{29}[hGH-RH(1-29)NH_{2} \ Peptide \ 79]$
 - $[CH_3(CH_2)_6CO\ -Tyr^1,\ D-Arg^2,\ Phe(pCI)^6,\ Ala^8,\ His^9,\ Tyr(Et)^{10},\ His^{11},\ Abu^{15},\ Nle^{27},\ D-Arg^{28},\ Har^{29}lhGH-RH(1-29)NH_2$ Peptide 80
- - $[HOOC(CH_2)_{12}CO\ -Tyr^1,\ D-Arg^2,\ Phe(pCl)^6,\ Ala^8,\ His^9,\ Tyr(Et)^{10},\ His^{11},\ Abu^{15},\ Nle^{27},\ D-Arg^{28},\ Har^{29}]nGH-RH(1-29)NH_2$ Peptide 82
- $[CH_3(CH_2)_6CO-Tyr^1, D-Arg^2, Phe(pCI)^6, Ala^8, Amp^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, His^{20}, Nle^{27}, D-Arg^{26}, \\ 20 \ Har^{29}]hGH-RH(1-29)NH_2 \\ Peptide 87$
 - [HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, His²⁰, Nle²⁷, D-Arg²⁸, Har²⁸]hGH-RH(1-29)NH₂ Peptide 88
- $25 \ [HOOC(CH_2)_{12}CO-Tyr^1, D-Arg^2, Phe(pCl)^6, Ala^8, Amp^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, His^{20}, Nle^{27}, D-Arg^{28}, \\ Har^{28}] hGH-RH(1-29)NH_2 \\ Peptide 89$
 - $[\text{1-Nac-Ty}^1, \text{D-Arg}^2, \text{Phe(pCl)}^6, \text{Ala}^6, \text{His}^9, \text{Tyr(El)}^{10}, \text{His}^{11}, \text{Abu}^{15}, \text{Nle}^{27}, \text{D-Arg}^{26}, \text{Har}^{23}] \text{hGH-RH(1-29)NH}_2$ Peptide 91
- $[CH_{3}(CH_{2})_{6}CO \ \ -Tyr^{1}, \ D-Arg^{2}, \ Phe(pCl)^{6}, \ His^{8}, \ Tyr(Et)^{10}, \ His^{11}, \ Abu^{15}, \ Nle^{27}, \ D-Arg^{28}, \ Har^{22}]nGH-RH(1-29)NH_{2}$ Peptide 92

- $[CH_{3}(CH_{2})_{e}CO Tyr^{1}, D Arg^{2}, Phe(pCI)^{6}, Ala^{8}, His^{9}, Cit^{16}, Nle^{27}, D Arg^{28}, Har^{29}]hGH RH(1-29)NH_{2}]$ Peptide 93
 - [CH₆(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, His¹⁵, His²⁰, Nle²⁷, D-Arg²⁸, Har²⁸]hGH-RH(1-29)NH₂ Peptide 94

 $[CH_{8}(CH_{2})_{8}CO - Tyr^{1}, D - Arg^{2}, Phe(pCl)^{6}, Ala^{8}, His^{9}, Tyr(El)^{10}, His^{11}, Orn^{12}, Abu^{15}, Orn^{21}, Nle^{27}, D - Arg^{28}, Har^{29}]hGH - RH(1 - 29)NH_{2} Peptide 95$

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(El)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²³, Orn²², Nie²², 5 D-Arg²⁸, Har²³]hGH-RH(1-29)NH₂ Peptide 96

 $[CH_{3}(CH_{2})_{6}CO\ \ -Tyr^{1},\ D-Arg^{2},\ Phe(pCl)^{6},\ Ala^{8},\ His^{9},\ Tyr(Et)^{10},\ His^{11},\ Abu^{15},\ Nle^{27},\ D-Arg^{26},\ Har^{29}]hGH-RH(1-29)NHEt$ Peptide 97

 $[CH_{3}(CH_{2})_{10}CO \ \ -Tyr^{1}, \ D-Arg^{2}, \ Phe(pCI)^{6}, \ Ala^{6}, \ His^{9}, \ Tyr(Et)^{10}, \ His^{11}, \ Abu^{15}, \ Nle^{27}, \ D-Arg^{26}, \ Har^{29}]hGH-RH(1-29)NHEt$ Peptide 99

[Hca -Tyr¹, D-Arg², Phe(pCl)², Ala², His³, Tyr(Et)¹0, His¹¹, Abu¹5, Nle²², D-Arg²², Har²²]hGH-RH(1-29)NHEt Peptide 100

15

30

 $[CH_3(CH_2)_6CO - Tyr^1, \ D-Arg^2, \ Phe(pCl)^6, \ Ala^6, \ His^9, \ Tyr(Et)^{10}, \ His^{11}, \ Abu^{15}, \ Nie^{27}, \ D-Arg^{28}, \ 20 \ Har^{29}]hGH-RH(1-29)NHMe \\ Peptide 101$

 $\begin{aligned} &[\text{HOOC(CH}_2)_{12}\text{CO -Tyr}^1, \text{ D-Arg}^2, \text{Phe(pCI)}^6, \text{ Ala}^8, \text{ His}^9, \text{Tyr(Et)}^{10}, \text{ His}^{11}, \text{ Orn}^{12}, \text{ Abu}^{15}, \text{ His}^{20}, \text{ Orn}^{21}, \\ &\text{Nle}^{27}, \text{ D-Arg}^{28}, \text{Ha}^{29}] \text{hGH-RH}(1\text{-}29) \text{NH}_2 \end{aligned} \end{aligned} \end{aligned} \end{aligned} \end{aligned} \end{aligned} \end{aligned}$

 $(\text{CH}_3(\text{CH}_2)_{\text{e}}\text{CO} \cdot \text{Tyr}^1, \text{ D-Arg}^2, \text{Phe}(\text{pCI})^6, \text{Als}^8, \text{His}^9, \text{Dip}^{10}, \text{His}^{11}, \text{Orn}^{12}, \text{Abu}^{15}, \text{His}^{20}, \text{Orn}^{21}, \text{Nie}^{27}, \text{D-Arg}^{28}, \text{Har}^{29}] \text{nGH-RH}(1\text{-}29) \text{NH}_2$ Peptide 104

 $(CH_{3}(CH_{2})_{6}CO - Tyr^{1}, D-Arg^{2}, Phe(pC))^{6}, Ala^{8}, His^{9}, Phe(pNO_{2})^{10}, His^{11}, Orn^{12}, Abu^{15}, His^{20}, Orn^{21}, Nle^{27}, D-Arg^{28}, Haz^{29}]hGH-RH(1-29)NH_{2}$ Peptide 105

 $[CH_{0}(CH_{2})_{6}CO - Tyr^{1}, D-Arg^{2}, Phe(pCl)^{6}, Ala^{8}, His^{9}, Tyr(El)^{10}, His^{11}, Orn^{12}, Abu^{15}, His^{20}, Orn^{21}, Nle^{27}, 35 \ D-Arg^{28}, Har^{29}]hGH-RH(1-29)NHEt Peptide 106$

 $[HOOC(CH_2)_{12}CO - Tyr^1, D - Arg^2, Phe(pCl)^6, Ala^8, Amp^9, Tyr(El)^{10}, His^{11}, Orn^{12}, Abu^{15}, His^{20}, Om^{21}, Nie^{27}, D - Arg^{26}, Har^{29}]hGH - RH(1 - 29)NH_2 \\ Peptide 107 \\ Peptide 107$

```
\begin{split} &[\text{HOOC(CH}_2)_{12}\text{CO} - \text{Tyr}^1, \text{D-Arg}^2, \text{Phe(pCl)}^6, \text{Ala}^8, \text{His}^9, \text{Dip}^{10}, \text{His}^{11}, \text{Orn}^{12}, \text{Abu}^{15}, \text{His}^{20}, \text{Orn}^{21}, \text{Nle}^{27}, \\ &\text{D-Arg}^{28}, \text{Har}^{28}|\text{hGH-RH}(1\text{-}29)\text{NH}_2 \end{split} \qquad \qquad \\ &\text{Peptide 108} \end{split}
```

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Phe(pNO₂)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, 5 Orn²¹, NIe²⁷, D-Arg²⁸, Hai²⁹)hGH-RH(1-29)NH₂ Peptide 109

 $[HOOC(CH_2)_{12}CO - Tyr^1, D - Arg^2, Phe(pCI)^6, Ala^8, His^9, Tyr(Et)^{10}, His^{11}, Orn^{12}, Abu^{15}, His^{20}, Orn^{21}, Nle^{27}, D - Arg^{28}, Har^{29}]hGH - RH(1 - 29)NHEt \\ Peptide 110$

10 [CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Dip¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹lnGH-RH(1-29)NH₂
Peptide 111

 $[CH_3(CH_2)_6CO - Tyr^1, D - Arg^2, Phe(pCl)^6, Ala^8, Amp^9, Phe(pNO_2)^{10}, His^{11}, Orn^{12}, Abu^{15}, His^{20}, Orn^{21}, Nie^{27}, D - Arg^{28}, Har^{29}]hGH - RH(1 - 29)NH_2 \\ Peptide 112$

 $[CH_3(CH_2)_6CO \ -Tyr^1, \ D-Arg^2, \ Phe(pCl)^6, \ Ala^8, \ Amp^9, \ Tyr(Et)^{10}, \ His^{11}, \ Orn^{12}, \ Abu^{15}, \ His^{20}, \ Orn^{21}, \ Nle^{27}, \ D-Arg^{28}, \ Har^{29} |hGH-RH(1-29)NHEt \\ Peptide 113$

[CH₃(CH₂)₈CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Dip¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nie²⁷, D-20 Ara²⁸, Hai²⁹lhGH-RH(1-29)NHEt Peptide 114

 $[CH_{8}(CH_{2})_{6}CO - Tyr^{1}, D - Arg^{2}, Phe(pC)]^{6}, Ala^{8}, His^{9}, Phe(pNO_{2})^{10}, His^{11}, Orn^{12}, Abu^{15}, His^{20}, Orn^{21}, Nle^{27}, D - Arg^{28}, Haz^{29}] hGH - RH(1-29) NHEt \\ Peptide 115$

25 [HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp³, Dip¹¹⁰, His¹¹, Orn¹², Abu¹⁵, His²³⁰, Orn²², Nle²², D-Arg²⁸⁰, Har²³]hGH-RH(1-29)NH₂ Peptide 116

 $[HOOC(CH_2)_{12}CO - Tyr^1, D-Arg^2, Phe(pCl)^6, Ala^8, Amp^9, Phe(pNO_2)^{10}, His^{11}, Orn^{12}, Abu^{15}, His^{20}, Orn^{21}, Nile^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2 \\ Peptide 117$

30

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁶, Amp⁹, Dip¹⁹, His¹¹, Orn¹², Abu¹⁵, His²⁹, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 118

 $[CH_{s}(CH_{2})_{6}CO - Tyr^{1}, D-Arg^{2}, Phe(pCI)^{6}, Ala^{8}, Amp^{9}, Phe(pNO_{2})^{10}, His^{11}, Orn^{12}, Abu^{15}, His^{20}, Orn^{21}, 35 \ Nie^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NHEt \\ Peptide 119$

 $[HOOC(CH_2)_{12}CO\ -Tyr^1,\ D-Arg^2,\ Phe(pCl)^6,\ Ala^8,\ Amp^9,\ Dip^{10},\ His^{11},\ Orn^{12},\ Abu^{15},\ His^{20},\ Om^{21},\ Nle^{27},\ D-Arg^{28},\ Har^{29}]hGH-RH(1-29)NHEt$ Peptide 120

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCI)⁶, Ala⁸, Amp⁹, Phe(pNO₂)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²², Orn²¹, NIe²⁷, D-Arg²⁸, Har²⁹lhGH-RH(1-29)NHEt Peptide 121

5 4. (ORIGINAL) A compound of claim 3 selected from the group consisting of :

[PhAc-Tyr¹, D-Arg², Phe(pCl)6, Amp9, Tyr(Me)¹0, Abu¹5, Nle²², D-Arg²8, Har²9]hGH-RH(1-29)NH₂ Peptide 67

10 [PhAc-Tyr.¹, D-Arg.², Phe(pC))⁶, His.⁹, Tyr(Me).¹⁰, Abu.¹⁵, Nle.²⁷, D-Arg.²⁸, Har.²⁹]hGH-RH(1-29)NH₂ Peptide 69

 $[{\rm CH_3(CH_{2)e}CO-Tyr^1}, \ D-Arg^2, \ Phe(pCl)^6, \ Amp^9, \ Tyr(Me)^{10}, \ Abu^{15}, \ Nle^{27}, \ D-Arg^{28}, \ Har^{29}]hGH-RH(1-29)NH_2 \\ Peptide \ 70$

15
[HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 72

 $[HOOC(CH_2)_{12}CO - Tyr^1, D-Arg^2, Phe(pCl)^6, Cit^8, Amp^9, Tyr(Me)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2 \\ Peptide 77$

25 $[CH_3(CH_2)_6CO \ -Tyr^1, \ D-Arg^2, \ Phe(pCl)^6, \ Cit^8, \ His^9, \ Tyr(Et)^{10}, \ His^{11}, \ Abu^{15}, \ Nle^{27}, \ D-Arg^{28}, \ Har^{28}[hGH-RH(1-29)NH_2 \ Peptide 79]$

 $[CH_3(CH_2)_eCO\ -Tyr^1,\ D-Arg^2,\ Phe(pCl)^6,\ Ala^8,\ His^9,\ Tyr(Et)^{10},\ His^{11},\ Abu^{15},\ Nle^{27},\ D-Arg^{28}, 30\ Har^{29}lhGH-RH(1-29)NH_2$ Peptide 80

[CH₈(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, His²⁰, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 86

 $(\text{CH}_3(\text{CH}_2)_6(\text{CO} - \text{Tyr}^1, \text{D-Arg}^2, \text{Phe}(\text{pCl})^6, \text{Ala}^8, \text{His}^9, \text{Tyr}(\text{Et})^{10}, \text{His}^{11}, \text{Orn}^{12}, \text{Abu}^{15}, \text{His}^{20}, \text{Orn}^{21}, \text{Nle}^{27}, \text{D-Arg}^{28}, \text{Har}^{29}] \text{nGH-RH}(1-29) \text{NH}_2 \\ \text{Peptide 96}$

5. (PRESENTLY AMENDED) A compound selected from the group consisting of:

 $\\ [\text{CH}_3(\text{CH}_2)_4\text{CO-Tyr}^1, \text{D-Arg}^2, \text{Phe(pCl)}^6, \text{Arg}^9, \text{Abu}^{15}, \text{Nie}^{27}, \text{D-Arg}^{26}, \text{Har}^{29}] \text{hGH-RH} \\ \text{Pentide 2}$

 $[HOOC(CH_2)_4CO-Tyr^1, D-Arg^2, Phe(pCl)^6, Arg^9, Abu^{15}, Nle^{27}, D-Arg^{26}, Har^{29}]hGH-RH(1-29)NH_2\\ 10 \qquad Peptide 3$

 $[\mathrm{CH_3(CH_2)_6CO-Tyr^1,D-Arg^2,Phe(pCl)^6,Arg^9,Abu^{15},Nle^{27},D-Arg^{28},Har^{29}}] h \mathrm{GH-RH} (1-29) \mathrm{NH_2} \\ \mathrm{Peptide}~4$

 $15 \ [HOOC(GH_2)_6CO-Tyr^1, D-Arg^2, Phe(pCl)^6, Arg^9, Abu^{15}, Nle^{27}, D-Arg^{26}, Har^{29}] hGH-RH(1-29)NH_2 \\ Peptide 5$

 $[CH_3(CH_2)_6CO\text{-Tyr}^1, D\text{-Arg}^2, Phe(pCl)^6, Arg^9, Abu^{15}, Nle^{27}, D\text{-Arg}^{28}, Har^{29}]hGH\text{-RH}(1\text{-}29)NH_2 \\ Peotide 6$

20

 $[HOOC(CH_2)_8CO-Tyr^1, D-Arg^2, Phe(pCI)^6, Arg^9, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 7

[CH₈(CH₂)₁₀CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
25 Peptide 8

 $[HOOC(CH_2)_{10}CO-Tyr^1,D-Arg^2,Phe(pCl)^6,Arg^9,Abu^{15},Nle^{27},D-Arg^{28},Har^{29}]hGH-RH(1-29)NH_2\\ Peptide~9$

 $30 \; [CH_3(CH_2)_{12}CO-Tyr^1, D-Arg^2, Phe(pCl)^6, Arg^9, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2 \\ Peptide \; 10$

[HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nie²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peotide 11

35

 $[CH_3(CH_2)_14CO-Tyr^1, D-Arg^2, Phe(pCl)^6, Arg^9, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2 \\ Peotide 12$

[HOOC(CH₂)₁₄CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 40 Peptide 13

- $[CH_3(CH_2)_6CO-Tyr^1,D-Arg^2,Phe(pCl)^6,Arg^9,Abu^{15},Nle^{27},Har^{28},D-Arg^{29}]hGH-RH(1-29)NH_2\\ Peptide 14$
- 5 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, NIe²⁷, Har²⁸, D-Arg²⁹]hGH-RH(1-29)NH₂ Peptide 15
 - $[CH_3(CH_2)_{14}CO\text{-Phe}^0, D\text{-Arg}^2, Phe(pCl)^6, Arg^9, Abu^{15}, Nle^{27}, D\text{-Arg}^{28}, Har^{29}] hGH\text{-RH} (1\text{-}29) NH_2 \\ Peptide 16$
- 10 [CH₉(CH₂)₁₄CO-D-Phe⁹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peotide 17
- $[PhAc\text{-}Arg^0, D\text{-}Arg^2, Phe(pCl)^6, Arg^9, Abu^{15}, Nle^{27}, D\text{-}Arg^{28}, Har^{29}]hGH\text{-}RH(1\text{-}29)NH_2 \\ 15 \qquad \qquad Peptide 18$
 - [PhAc-D-Arg⁹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, NIe²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 19
- 20 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 21
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Cit⁹, Abu¹⁵, Nle²², D-Arg²⁸, Har²³]hGH-RH(1-29)NH₂ Peptide 22
 - [Phac-Tyr¹, D-Arg², Phe(pCi)⁶, Cit⁶, Arg³, Abu¹⁵, Nie²⁷, Har²⁸, D-Arg²³]hGH-RH(1-29)NH₂ Peptide 23
- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Cit⁹, Abu¹⁵, Nle²⁷, Har²⁸, D-Arg²⁹]hGH-RH(1-29)NH₂ 30 Peptide 24
 - $[HOOC(CH_2)_{12}CO-Tyr^1, D-Arg^2, Phe(pCl)^6, Cit^8, Cit^9, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{28}]hGH-RH(1-29)NH_2 \\ Peptide 25$
- 35 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, D-Ala⁸, Arg⁹, Abu¹⁵, Nie²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 26
 - [PhAc-Tyr⁴, D-Arg², Phe(pCl)⁶, Abu⁶, Arg⁶, Abu⁴⁶, Nle²⁴, D-Arg²⁶, Har²⁰]hGH-RH(1-29)NH₂
 ——Poptide-27

- . [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁹, Abu¹⁵, Nle²⁷, Har²⁸, D-Arg²⁹]hGH-RH(1-29)NH₂ Peptide 28
- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Amp¹0, Abu¹5, Nle²7, D-Arg²8, Har²9]hGH-RH(1-29)NH₂ 5 Peptide 30
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Amp¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁸]hGH-RH(1-29)NH₂ Peptide 31
- 10 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, His¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁶, Har²⁹]hGH-RH(1-29)NH₂ Peptide 32
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Cha¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁸]hGH-RH(1-29)NH₂ Peptide 33
- 15
 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har², Tpi¹0, Abu¹5, Nle²7, D-Arg²8, Har²³]hGH-RH(1-29)NH₂
 Pentida 34
- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, 2-Nal¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 20 Peptide 35
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Dip¹⁰, Abu¹⁵, NIe²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 36
- $25 \; [\text{PhAc-Tyr}^1, \text{D-Arg}^2, \text{Phe}(\text{pCl})^6, \text{Har}^9, \text{Phe}(\text{pNH}_2)^{10}, \text{Abu}^{15}, \text{Nle}^{27}, \text{D-Arg}^{28}, \text{Har}^{29}] \text{hGH-RH}(1\text{-}29) \text{NH}_2 \\ \text{Peptide } 37 \; \\$
 - $[PhAc-Tyr^1, D-Arg^2, Phe(pCl)^6, Har^9, Trp^{10}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peotide 38

- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Phe(pNO₂)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²²]hGH-RH(1-29)NH₂
 Peotide 39
- $[PhAc-Tyr^{1}, D-Arg^{2}, Phe(pCl)^{6}, Har^{9}, 3-Pal^{10}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_{2}$ 35 Peptide 40
 - $$\label{eq:continuous} \begin{split} &[\text{PhAc-Tyr}^1, \text{D-Arg}^2, \text{Phe(pCl)}^6, \text{Har}^9, \text{Tyr(Et)}^{10}, \text{Abu}^{15}, \text{Nle}^{27}, \text{D-Arg}^{28}, \text{Har}^{29}] \text{hGH-RH} \\ &\text{Peptide 41} \end{split}$$

- : [PhAc-His¹, D-Arg², Tyr⁶, Har⁹, Bpa¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peotide 42
- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Har¹², Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 5 Peptide 43
 - [Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nie²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 45
- 10 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nie²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peotide 46
 - [Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 47
- 15

 [PhAc-Tyr¹, D-Arg², Phe(pCl)6, Arg³, Abu¹⁵, Nie²7, D-Arg²a, Har²a]hGH-RH(1-29)NHEt

 Pentide 48
- [PhAc-Tyr 1 , D-Arg 2 , Phe(pCl) 6 , Har 9 , Tyr(Me) 10 , Aib 15 , Nie 27 , D-Arg 26 , Har 29]hGH-RH(1-29)NHEt 20 Peptide 49
 - $\begin{tabular}{ll} $[PhAc-Tyr^1, D-Arg^2, Phe(pCl)^6, Har^9, Tyr(Me)^{10}, Orn^{12}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NHEt \\ \begin{tabular}{ll} $Peptide 50 \end{tabular} \end{tabular}$
- 25 [Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Agm²⁹]hGH-RH(1-29) Peptide 51

- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Agm²⁹]hGH-RH(1-29) Peptide 52
- [Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har³, Tyr(Me)¹⁰, Abu¹⁵, Nie²⁷, D-Arg²⁸, Har²⁸, Har²⁵]hGH-RH(1-30)NH₂ Peptide 53
- $[Dat-Tyr^{1}, D-Arg^{2}, Phe(pCl)^{6}, Har^{9}, Tyr(Me)^{10}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}, Har^{30}]hGH-RH(1-30)NH_{2}$ 35 Peptide 54
 - [lpa-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹, Har³⁰]hGH-RH(1-30)NH₂ Peptide 55

```
. [Hca-Tyr¹, D-Arg², Phe(pCl)<sup>6</sup>, Har<sup>9</sup>, Tyr(Me)<sup>10</sup>, Abu<sup>15</sup>, Nle², D-Arg², Har², Har³, har², har²,
```

[Hca-Tyr¹, D-Arg², Phe(pCl) 6 , Har 9 , Tyr(Me) 10 , Abu 15 , Nle 27 , D-Arg 28 , D-Arg 29 , Har 30]hGH-RH(1-5 30)NH $_2$ Peptide 57

[Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har³, Tyr(Me)¹⁰, Abu¹⁵, Nle², D-Arg², Har², D-Arg³)]hGH-RH(1-30)NH₂ Peotide 58

10 [Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har³, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²³, Har²³, Agm³⁰]hGH-RH(1-30) Peptide 59

[PhAc-Tyr¹, D-Arg², Phe(pCt)6, Har³, Tyr(Me)¹0, Abu¹5, Nle²², D-Arg²8, Har²9, Agm³3]hGH-RH(1-30) Peptide 60

 $[PhAc-Tyr^1, D-Arg^2, Phe(pCl)^6, Har^9, Tyr(Me)^{10}, Har^{11}, Abu^{15}, Nle^{27}, D-Arg^{23}, Har^{29}] hGH-RH (1-20 29) NH_2 \\ Peptide 63$

 $[PhAc-Tyr^1, D-Arg^2, Phe(pCl)^6, Har^9, Tyr(Me)^{10}, Amp^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{23}]hGH-RH(1-29)NH_2 \\ Peptide 64$

25 [PhAc-Tyr¹, D-Arg², Phe(pCI)⁶, Har³, Tyr(Me)¹0, Cit¹¹, Abu¹⁵, Nle²², D-Arg²³, Har²³]nGH-RH(1-29)NH₂ Peptide 65

 $[PhAc-Tyr^{1}, \ D-Arg^{2}, \ Phe(pCl)^{6}, \ Har^{9}, \ Tyr(Me)^{10}, \ Abu^{15}, \ His^{20}, \ Nle^{27}, \ D-Arg^{20}, \ Har^{23}]hGH-RH(1-29)NH_{2}$ Peptide 84

 $[PhAc-Tyr^1, D-Arg^2, Phe(pCl)^6, Har^9, Tyr(Me)^{10}, His^{11}, Abu^{15}, His^{20}, Nle^{27}, D-Arg^{26}, Har^{22}] hGH-RH(1-29)NH_2 \\ Peptide 85$

- 16. (PREVIOUSLY AMENDED)The method of suppressing IGF-I or IGF-II levels in the tumor tissue of a patient having a cancer carrying receptors for IGF-I by administering to said patient a suppressively effective amount of a compound of claim 1
- 5 17. (PREVIOUSLY AMENDED)The method of suppressing VEGF levels in the tumor tissue of a patient having a cancer by administering to said patient a suppressively effective amount of a compound of claim 1.
- 18. (PREVIOUSLY AMENDED)The method of suppressing levels of IGF-I in a patient in 10 need of same by administering to said patient a suppressively effective amount of a compound of claim 1.
- 19. (PREVIOUSLY AMENDED) The method of suppressing serum IGF-I levels in a patient having a cancer carrying receptors for IGF-I by administering to said patient a suppressively 15 effective amount of a compound of claim 1.
- 20. (PREVIOUSLY AMENDED)The method of suppressing GH levels in a patient having a cancer carrying receptors for IGF-I or GH by administering to said patient a suppressively effective amount of a compound of claim 1.
 20
 - 21. Cancelled
- 22. (PRESENTLY AMENDED) A pharmacologically administrable composition for the suppression of levels of GH in a patient consisting essentially of a compound of claim 1 and a 25 pharmacologically acceptable carrier.
 - 23. 28 Cancelled